EP4045062A1 — Modulators of pnpla3 expression
Assigned to AstraZeneca AB · Expires 2022-08-24 · 4y expired
What this patent protects
The present embodiments provide methods, compounds, and compositions useful for inhibiting PNPLA3 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PNPLA3. In some embodiments, the methods, compounds, and compositions are useful f…
USPTO Abstract
The present embodiments provide methods, compounds, and compositions useful for inhibiting PNPLA3 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PNPLA3. In some embodiments, the methods, compounds, and compositions are useful for treating, preventing, or ameliorating a disease associated with PNPLA3 having an I148M mutation.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.